Literature DB >> 24331074

A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data.

Cecilia P Chung1, Patricia Rohan2, Shanthi Krishnaswami3, Melissa L McPheeters4.   

Abstract

PURPOSE: To review the evidence supporting the validity of billing, procedural, or diagnosis code, or pharmacy claim-based algorithms used to identify patients with rheumatoid arthritis (RA) in administrative and claim databases.
METHODS: We searched the MEDLINE database from 1991 to September 2012 using controlled vocabulary and key terms related to RA and reference lists of included studies were searched. Two investigators independently assessed the full text of studies against pre-determined inclusion criteria and extracted the data. Data collected included participant and algorithm characteristics.
RESULTS: Nine studies reported validation of computer algorithms based on International Classification of Diseases (ICD) codes with or without free-text, medication use, laboratory data and the need for a diagnosis by a rheumatologist. These studies yielded positive predictive values (PPV) ranging from 34 to 97% to identify patients with RA. Higher PPVs were obtained with the use of at least two ICD and/or procedure codes (ICD-9 code 714 and others), the requirement of a prescription of a medication used to treat RA, or requirement of participation of a rheumatologist in patient care. For example, the PPV increased from 66 to 97% when the use of disease-modifying antirheumatic drugs and the presence of a positive rheumatoid factor were required.
CONCLUSIONS: There have been substantial efforts to propose and validate algorithms to identify patients with RA in automated databases. Algorithms that include more than one code and incorporate medications or laboratory data and/or required a diagnosis by a rheumatologist may increase the PPV.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  A; ACR; AMI; ANA; Administrative database; Algorithm; American College of Rheumatology; CD; CI; CPT; Crohn's disease; DB; DMARD; DMBA; Deseret Mutual Benefits Administration; EDC; EMR; GHS; Geisinger health system; HCPCS; HZ; Health Care Financing Administration Common Procedure Coding System; IBD; ICD; ICD-9; International Classification of Diseases; JRA; KPNC; Kaiser Permanente Northern California; MEDECHO; MTX; Maintenance et Exploitation des Donnees pour l’Etude de la Clientele Hospitaliere; NDC; NJ; NMSC; NPV; NSAID; National Drug Code; New Jersey; OSHPD; Office of Statewide Health Planning and Development; PA; PACE; PPV; Pennsylvania; Pennsylvania Assistance Contract for the Elderly; Positive predictive value; PsA; RA; RAMQ; RF; ROC; RX; Regie de l’assurance maladie du Quebec; Rheumatoid arthritis; SLE; THR; VA; VAMC; VISN; Validation; Veterans Affairs Medical Center; Veterans Affairs/Administration; Veterans Integrated Services Network; acute myocardial infarction; algorithm; anti-CCP; anti-TNF; anti-cyclic citrullinated peptide; anti-tumor necrosis factor; antinuclear antibody; confidence interval; current procedural terminology; database; disease-modifying antirheumatic drug; electronic medical records; estimated date of conception; herpes zoster; inflammatory bowel disease; juvenile-onset rheumatoid arthritis; methotrexate; negative predictive value; non-melanoma skin cancer; non-steroidal anti-inflammatory drug; positive predictive value; prescription; psoriatic arthritis; receiver operating characteristic (curve area); rheumatoid arthritis; rheumatoid factor; systemic lupus erythematosus; total hip replacement

Mesh:

Year:  2013        PMID: 24331074     DOI: 10.1016/j.vaccine.2013.03.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  46 in total

1.  Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study.

Authors:  Andrew D Wiese; Marie R Griffin; C Michael Stein; Edward F Mitchel; Carlos G Grijalva
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

2.  Performance of Administrative Algorithms to Identify Interstitial Lung Disease in Rheumatoid Arthritis.

Authors:  Bryant R England; Punyasha Roul; Tina D Mahajan; Namrata Singh; Fang Yu; Harlan Sayles; Grant W Cannon; Brian C Sauer; Joshua F Baker; Jeffrey R Curtis; Ted R Mikuls
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-10       Impact factor: 4.794

3.  Leveraging Big Data to Transform Drug Discovery.

Authors:  Benjamin S Glicksberg; Li Li; Rong Chen; Joel Dudley; Bin Chen
Journal:  Methods Mol Biol       Date:  2019

4.  Key considerations when using health insurance claims data in advanced data analyses: an experience report.

Authors:  Renata Konrad; Wenchang Zhang; Margrét Bjarndóttir; Ruben Proaño
Journal:  Health Syst (Basingstoke)       Date:  2019-03-01

5.  Power in numbers.

Authors:  Evelyne Vinet; Eliza F Chakravarty; Megan E B Clowse
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

6.  Approaches to Supporting the Analysis of Historical Medication Datasets with RxNorm.

Authors:  Lee B Peters; Olivier Bodenreider
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

7.  Bias from outcome misclassification in immunization schedule safety research.

Authors:  Sophia R Newcomer; Martin Kulldorff; Stan Xu; Matthew F Daley; Bruce Fireman; Edwin Lewis; Jason M Glanz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-01-02       Impact factor: 2.890

8.  Preterm birth phenotypes in women with autoimmune rheumatic diseases: a population-based cohort study.

Authors:  K D Kolstad; J A Mayo; L Chung; Y Chaichian; V M Kelly; M Druzin; D K Stevenson; G M Shaw; J F Simard
Journal:  BJOG       Date:  2019-10-31       Impact factor: 6.531

9.  Staphylococcus aureus sepsis in rheumatoid arthritis.

Authors:  Michael Sams; Margaret A Olsen; Reeti Joshi; Prabha Ranganathan
Journal:  Rheumatol Int       Date:  2015-03-11       Impact factor: 2.631

10.  [Prevalence of rheumatoid arthritis in Germany based on health insurance data : Regional differences and first results of the PROCLAIR study].

Authors:  S Hense; A Luque Ramos; J Callhoff; K Albrecht; A Zink; F Hoffmann
Journal:  Z Rheumatol       Date:  2016-10       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.